FDA issues Fast Track Designation to Sopherion Therapeutics' Myocet

[News]

Sopherion Therapeutics, LLC, a biopharmaceutical company focused on the development and commercialization of anti-cancer therapies, announced today that it has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for nonpegylated liposomal doxorubicin (Myocet(TM)) for first-line therapy of HER2 positive metastatic breast cancer.

More... (http://www.news-medical.net/news/20100107/FDA-issues-Fast-Track-Designation-to-Sopherion-Therapeutics-Myocet.aspx)